Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a negative sentiment due to a 20% decline in revenue and increased net loss, coupled with higher R&D expenses. The lack of strategic initiatives and shareholder return discussion further dampens the outlook. Despite potential in Rezpegaldesleukin, the absence of concrete advancements or partnerships, combined with the risks in forward-looking statements, contributes to a negative sentiment. The cash position decrease also raises concerns about financial health, leading to a likely negative stock price movement.
Key Financial Performance
Revenue Nektar Therapeutics reported revenue of $25 million for Q1 2026, which represents a 20% decrease year-over-year. The decline was attributed to reduced licensing revenue from partnerships.
Net Loss The company reported a net loss of $45 million for Q1 2026, compared to a net loss of $40 million in Q1 2025. The increase in net loss was due to higher R&D expenses related to ongoing clinical trials.
Research and Development (R&D) Expenses R&D expenses increased to $30 million in Q1 2026, up from $25 million in Q1 2025, reflecting the advancement of key clinical programs.
General and Administrative (G&A) Expenses G&A expenses were $10 million in Q1 2026, consistent with the $10 million reported in Q1 2025, indicating stable administrative costs.
Cash and Cash Equivalents The company ended Q1 2026 with $200 million in cash and cash equivalents, down from $250 million at the end of Q1 2025. The decrease was primarily due to increased spending on R&D activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rezpegaldesleukin Development: Discussion on therapy potential and development plans for rezpegaldesleukin.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements about therapy potential, development plans, clinical data presentations, and regulatory interactions are inherently subject to uncertainties and risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blair LLC
Citigroup Inc
Cowen Research
Director Jonathan
Division Cha
Division Jay
Division Marc
Division PM
Division Samantha
Division Tsan
Dominic Lorenzi
EDT Nektar
Frahm TD
Gardiner Interim
Inc Research
Interim Chief
Jay Olson
Jonathan Zalevsky
LLC Research
Lorenzi Piper
Marc Frahm
Officer Gardiner
Officer Tagliaferri
Relations statement
Research Division
TD Cowen
Yu
Zalevsky Senior
expectation presentation
interaction statement
presentation interaction
statement therapy
timing expectation
NKTR Transcript
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reveals a negative sentiment due to a 20% decline in revenue and increased net loss, coupled with higher R&D expenses. The lack of strategic initiatives and shareholder return discussion further dampens the outlook. Despite potential in Rezpegaldesleukin, the absence of concrete advancements or partnerships, combined with the risks in forward-looking statements, contributes to a negative sentiment. The cash position decrease also raises concerns about financial health, leading to a likely negative stock price movement.
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. The financial performance shows a decrease in revenue but an improved net loss and positive cash flow, leading to a neutral sentiment. The development plans for Rezpegaldesleukin and future data presentations are positive, but the lack of discussion on shareholder returns and inherent risks in forward-looking statements balance this out. The Q&A section did not provide additional insights to shift the sentiment significantly. Overall, the stock price is likely to remain stable over the next two weeks.
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Positive11-7
Despite some unclear management responses, the earnings call highlights strong market opportunities for REZPEG, particularly in atopic dermatitis and alopecia areata. The company's financial guidance shows a healthy cash runway, and the potential differentiation of REZPEG from competitors is promising. The Q&A section reveals significant interest in REZPEG's unique mechanism and its potential safety advantages over JAK inhibitors. Overall, these factors suggest a positive sentiment towards Nektar's future prospects, supporting a positive stock price movement prediction.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary indicates a strong financial position and optimistic guidance, which are positive factors. However, there are concerns about high R&D expenses, projected net losses, and ongoing litigation with Lilly. The Q&A reveals management's active engagement in partnerships and confidence in product development, but also highlights uncertainties in litigation and lack of specific benchmarks for remittive effects. These mixed signals suggest a neutral impact on stock price, especially given the absence of a market cap for further context.
NKTR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
